Mechanism-based covalent neuraminidase inhibitors with broad spectrum influenza antiviral activity

J-H Kim, R Resende, T Wennekes, H-M Chen, N Bance, S Buchini, Andrew G Watts, P Pilling, V A Streltsov, M Petric, R Liggins, S Barrett, J L Mckimm-Breschkin, M Niikura, S G Withers

Research output: Contribution to journalArticlepeer-review

165 Citations (SciVal)
517 Downloads (Pure)


Influenza antiviral agents play important roles in modulating disease severity and in controlling pandemics while vaccines are prepared, but the development of resistance to agents like the commonly used neuraminidase inhibitor oseltamivir may limit their future utility. We report here a new class of specific, mechanism-based anti-influenza drugs that function via the formation of a stabilized covalent intermediate in the influenza neuraminidase enzyme, and confirm this mode of action via structural and mechanistic studies. These compounds function in cell-based assays and in animal models, with efficacies comparable to that of the neuraminidase inhibitor zanamivir and with broad spectrum activity against drug-resistant strains in vitro. The similarity of their structure to that of the natural substrate and their mechanism-based design make these attractive antiviral candidates.
Original languageEnglish
Pages (from-to)71-75
Number of pages5
Issue number6128
Early online date21 Feb 2013
Publication statusPublished - 5 Apr 2013


Dive into the research topics of 'Mechanism-based covalent neuraminidase inhibitors with broad spectrum influenza antiviral activity'. Together they form a unique fingerprint.

Cite this